{"product_id":"zivo-vrio-analysis","title":"ZIVO Bioscience, Inc. (ZIVO): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eWhat truly fuels ZIVO Bioscience, Inc. (ZIVO)'s success? Dive into our distilled VRIO Analysis to instantly uncover the core of its competitive advantage - examining the Value, Rarity, Inimitability, and Organization of its key assets. See precisely where ZIVO Bioscience, Inc. (ZIVO) stands in the market and why its current strengths may or may not be sustainable by reading the full breakdown below.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eZIVO Bioscience, Inc. (ZIVO) - VRIO Analysis: 1. Proprietary Algal Strain Portfolio\n\u003c\/h2\u003e\n\u003cp\u003eYou’re looking at the core asset for ZIVO Bioscience, Inc. (ZIVO), and honestly, it’s the engine for everything they are trying to build in biotech and agtech. This proprietary algal strain portfolio is what separates them from a generic ingredient supplier. Let’s break down its competitive standing using the VRIO framework, keeping our eye on the numbers from their latest filings.\u003c\/p\u003e\n\n\u003cp\u003eThe value proposition here is clear: these are optimized freshwater strains that are \u003cstrong\u003enon-GMO\u003c\/strong\u003e and antibiotic-free, which is a big deal for both human nutrition and animal therapeutics. Think about their focus areas - they are developing compounds to support healthy immune response in humans and for specific animal challenges like bovine mastitis and avian influenza. The entire business model, which is still heavily R\u0026amp;D focused, hinges on extracting unique bioactive molecules from this specific biomass. For the nine months ending September 30, 2025, the company reported revenue of only \u003cstrong\u003e$119,025\u003c\/strong\u003e, showing that the value is currently potential, tied directly to successfully commercializing this platform.\u003c\/p\u003e\n\n\u003cp\u003eHere’s the quick math on the strain’s competitive standing:\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eVRIO Dimension\u003c\/td\u003e\n    \u003ctd\u003eAssessment\u003c\/td\u003e\n    \u003ctd\u003eSupporting Data\/Context (2025 Fiscal Year)\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eYes\u003c\/td\u003e\n    \u003ctd\u003eProvides unique, non-GMO starting material for all product lines, directly supporting health claims in both human and animal markets. Focus on immune-enhancing compounds for poultry and mastitis treatments.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eYes\u003c\/td\u003e\n    \u003ctd\u003eThe specific, optimized freshwater strains are unique to ZIVO Bioscience. Their IP portfolio explicitly includes proprietary algal and bacterial strains.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eDifficult\u003c\/td\u003e\n    \u003ctd\u003eResult of dedicated R\u0026amp;D, protected by IP. Core IP includes the algae culture and the \u003cstrong\u003epatented process\u003c\/strong\u003e of producing that culture. They are actively filing patent applications in Taiwan, India, and mainland China.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eYes, but Strained\u003c\/td\u003e\n    \u003ctd\u003eThe entire strategy hinges on these strains, with active scale-up efforts via licensing in India and Taiwan. However, the organization is under significant financial pressure: Net loss for the first nine months of 2025 was \u003cstrong\u003e$(6,884,474)\u003c\/strong\u003e, and cash on hand as of September 30, 2025, was just \u003cstrong\u003e$57,222\u003c\/strong\u003e.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eSustained (Conditional)\u003c\/td\u003e\n    \u003ctd\u003eSustained, provided the IP protection remains robust and the company can secure the estimated \u003cstrong\u003e$6.0 million\u003c\/strong\u003e needed to fund operations over the next 12 months.\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe difficulty in imitation is rooted in the combination of the strain itself and the patented production methodology. They have optimized for robustness, high yield, and a bland taste, which makes it easier and less expensive to grow organically than some other commercial strains. To be fair, the company is actively trying to organize for scale, shipping starter inoculum to Taiwan and working with established growers in India to convert ponds to ZIVO strain production - it's a capital-efficient approach to scale-up.\u003c\/p\u003e\n\n\u003cp\u003eWhat this estimate hides is the execution risk. While the asset is theoretically a sustained advantage, the current financial state suggests the organization is struggling to bridge the gap between R\u0026amp;D and commercial revenue. If onboarding takes 14+ days, churn risk rises, which is a general business risk, but here, the immediate risk is liquidity. The current structure is set up to exploit this asset, but the balance sheet needs shoring up.\u003c\/p\u003e\n\n\u003cp\u003eKey elements supporting the advantage include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eProprietary culture and \u003cstrong\u003epatented\u003c\/strong\u003e production process.\u003c\/li\u003e\n\u003cli\u003eHigh yield and low startup cost cultivation.\u003c\/li\u003e\n\u003cli\u003eBland taste profile for food applications.\u003c\/li\u003e\n\u003cli\u003eActive international IP filings (Taiwan, India, China).\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eZIVO Bioscience, Inc. (ZIVO) - VRIO Analysis: 2. Cost-Efficient Cultivation Methodology\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Lowers the barrier to scale by using basic, shallow pond systems instead of costly fermentation or photobioreactors, aiming for affordability.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eCultivation System\u003c\/th\u003e\n\u003cth\u003eEstimated Capital Cost per Square Foot\u003c\/th\u003e\n\u003cth\u003eBiomass Production Cost (Example Basis)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhotobioreactor (PBR) Baseline\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$9.29\u003c\/strong\u003e (approximate)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$5.30\/kg\u003c\/strong\u003e (Horizontal Tubular PBR, 2010 Euros)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOpen Pond System\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$0.87\u003c\/strong\u003e (approximate)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e€4.95\/kg\u003c\/strong\u003e (Open Ponds, 2010 Euros)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e This specific, low-complexity model for high-quality algae production is not common among peers.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eInitial biomass cultivation was carried in small bioreactors and indoor ponds, expected to move to larger, outdoor ponds.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Costly to imitate because it requires deep process knowledge to maintain yield and quality in a simple setup.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The company is actively designing facilities to duplicate this low-cost approach.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTrailing 12-Month Revenue (as of 30-Sep-2025): \u003cstrong\u003e$209K\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eOperating Expenses (Fiscal Year ending 2024-12-31): \u003cstrong\u003e$13.52M\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eTotal Assets (as of 30-Sep-2025, TTM in Thousands USD): \u003cstrong\u003e559\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe company signed a contract manufacturing agreement with Alimenta Algae SAC to grow and process algal biomass in Peru.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained, as cost parity is a key differentiator in the feed market.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNet Income (2024): \u003cstrong\u003e-$13.38 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNet Income (TTM in Thousands USD): \u003cstrong\u003e(8,486)\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eZIVO Bioscience, Inc. (ZIVO) - VRIO Analysis: 3. Dual-Market Platform Versatility\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Allows ZIVO Bioscience to address two large, growing markets - human nutraceuticals and animal feed\/supplements, spreading risk and maximizing IP application.\u003c\/p\u003e\n\u003cp\u003eThe animal health sector presents significant scale, with the global animal feed market valued at \u003cstrong\u003e$465.65 billion\u003c\/strong\u003e in 2024, projected to reach \u003cstrong\u003e$705.15 billion\u003c\/strong\u003e by 2034. The global animal feed supplements market reached \u003cstrong\u003e$38.20 billion\u003c\/strong\u003e in 2024. The companion animal vaccines market was valued at \u003cstrong\u003e$5.43 billion\u003c\/strong\u003e in 2024, and the U.S. pet supplement market surpasses \u003cstrong\u003e$2.7B\u003c\/strong\u003e annually. For 2024, ZIVO Bioscience reported revenue of \u003cstrong\u003e$157,220\u003c\/strong\u003e, a \u003cstrong\u003e468.61%\u003c\/strong\u003e increase year-over-year.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e No, many biotech firms target both, but the specific algae platform is unique.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Easy to imitate the strategy, but hard to imitate the platform itself.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Yes, they have distinct development tracks for Bovine Mastitis and Human Immune Modulation.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eBovine Mastitis Development:\u003c\/strong\u003e Preliminary pilot study results indicated a noticeable decrease in the number and viability of Mycoplasma organisms in treated cows compared to an untreated control group infected with the same pathogen.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eHuman Nutrition Development:\u003c\/strong\u003e The self-affirmed GRAS process for ZIVO algal biomass was updated in May 2023 to validate its suitability as a safe product for human consumption.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMarket Segment\u003c\/th\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eYear\/Projection\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal Animal Feed\u003c\/td\u003e\n\u003ctd\u003eValuation\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$465.65 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal Animal Feed Supplements\u003c\/td\u003e\n\u003ctd\u003eValuation\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$38.20 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVeterinary Supplements\u003c\/td\u003e\n\u003ctd\u003eProjected Valuation\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$15.2 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2031\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAntibiotic-free Livestock Feed\u003c\/td\u003e\n\u003ctd\u003eCAGR Forecast\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e8.2%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eto 2033\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompanion Animal Vaccines\u003c\/td\u003e\n\u003ctd\u003eProjected Valuation\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$8.71 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2032\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eZIVO Revenue\u003c\/td\u003e\n\u003ctd\u003eAmount\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$157,220\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary, as the dual-focus strategy is easily copied if the core tech is replicated.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eZIVO Bioscience, Inc. (ZIVO) - VRIO Analysis: 4. Secured Production Capacity \u0026amp; Offtake\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides a tangible path to revenue realization and de-risks scale-up; the Peru site build-out aims for $\\sim\\mathbf{100,000}$ kg\/year capacity in late $\\mathbf{2025}$.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Yes, having contracted facilities and an offtake agreement (like the one with ZWorldwide, Inc.) is rare for a company with $\\mathbf{\\$209K}$ TTM revenue (as of Sep 30, 2025).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Difficult, as it involves multi-year contracts and capital commitments from partners, specifically Alimenta Algae SAC making necessary investments to cultivation ponds and downstream processing.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Yes, through the ZIVOLife, LLC subsidiary managing the manufacturing contracts, committing to purchase all output from the Alimenta Algae facility in Peru.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained, as long-term supply agreements lock in future sales volume, with ZWorldwide committing to minimum annual purchases through August 31, $\\mathbf{2028}$.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003ePartner\/Entity\u003c\/td\u003e\n\u003ctd\u003eTimeline\/Reference\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTarget Annual Capacity\u003c\/td\u003e\n\u003ctd\u003e$\\mathbf{100,000}$ kg\u003c\/td\u003e\n\u003ctd\u003eAlimenta Algae SAC (Peru Site)\u003c\/td\u003e\n\u003ctd\u003eAnticipated fully operational in Q2\/Q3 $\\mathbf{2025}$\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMinimum Annual Offtake Commitment\u003c\/td\u003e\n\u003ctd\u003e$\\mathbf{24,000}$ kg\u003c\/td\u003e\n\u003ctd\u003eZWorldwide, Inc.\u003c\/td\u003e\n\u003ctd\u003eFor five years subject to contingencies\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOfftake Purchase Obligation End Date\u003c\/td\u003e\n\u003ctd\u003eAugust 31, $\\mathbf{2028}$\u003c\/td\u003e\n\u003ctd\u003eZIVOLife, LLC \/ Alimenta\u003c\/td\u003e\n\u003ctd\u003eContract Manufacturing Term Sheet\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct Purchases (FY $\\mathbf{2024}$)\u003c\/td\u003e\n\u003ctd\u003e$\\mathbf{\\$108,268}$\u003c\/td\u003e\n\u003ctd\u003eZIVOLife, LLC\u003c\/td\u003e\n\u003ctd\u003eUnder Term Sheet\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct Purchases (FY $\\mathbf{2023}$)\u003c\/td\u003e\n\u003ctd\u003e$\\mathbf{\\$16,040}$\u003c\/td\u003e\n\u003ctd\u003eZIVOLife, LLC\u003c\/td\u003e\n\u003ctd\u003eUnder Term Sheet\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eSpecific Contractual Details:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eZWorldwide, Inc. holds exclusive rights to the Zivolife product as a food or food additive for human use in North America.\u003c\/li\u003e\n\u003cli\u003eZWorldwide committed to purchasing the entire supply of Zivolife produced for the initial $\\mathbf{18}$ months.\u003c\/li\u003e\n\u003cli\u003eThe Contract Manufacturing Term Sheet commits ZIVOLife, LLC to purchase all Zivolife${\\text{TM}}$ product produced by Alimenta at the Peru site.\u003c\/li\u003e\n\u003cli\u003eThe global food and beverage microalgae market is projected to reach $\\mathbf{\\$247}$ million by $\\mathbf{2033}$.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eZIVO Bioscience, Inc. (ZIVO) - VRIO Analysis: 5. Patented Bioactive Molecule IP\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eVRIO Component Analysis:\u003c\/strong\u003e\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eValue\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eProtects specific compounds derived from the algae, enabling out-licensing opportunities to pharmaceutical and feed companies. The IP portfolio supports applications targeting Bovine Mastitis, Canine Joint Health, Human Immune Modulation, Companion Animal Food Ingredient, NDI, and Skin Health.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eRarity\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003e\u003cstrong\u003eYes\u003c\/strong\u003e, patented inventions are inherently rare. The company holds US Patent No. \u003cstrong\u003e9,486,005\u003c\/strong\u003e for 'Agents and Mechanisms for Treating Hypercholesterolemia,' issued November 17, 2016.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eImitability\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003e\u003cstrong\u003eVery difficult\u003c\/strong\u003e; patents offer the strongest legal barrier to imitation. The IP portfolio includes proprietary algal strains, bioactive molecules, and production techniques.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eOrganization\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003e\u003cstrong\u003eYes\u003c\/strong\u003e, the R\u0026amp;D process is explicitly structured around developing efficacy claims and securing compliance data for licensing. The Company is a licensor of internally developed intellectual property.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003e\u003cstrong\u003eSustained\u003c\/strong\u003e, as long as patents remain in force. The Company began ZivolifeTM sales in June 2023, following a self-affirmed GRAS status updated in May 2023.\u003c\/p\u003e\n\u003cp\u003eThe intellectual property portfolio underpins commercial agreements, such as the offtake agreement with ZWorldwide, Inc., which includes provisions to purchase at least \u003cstrong\u003e24,000 kg\u003c\/strong\u003e per year for a minimum of five years.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePatented IP and Associated Applications:\u003c\/strong\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003ePatent\/Filing Status\u003c\/th\u003e\n\u003cth\u003eIssuance\/Filing Date\u003c\/th\u003e\n\u003cth\u003eApplication Area\u003c\/th\u003e\n\u003cth\u003eTarget Market Context (Example)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS Patent No. 9,486,005\u003c\/td\u003e\n\u003ctd\u003eNovember 17, 2016\u003c\/td\u003e\n\u003ctd\u003eCholesterol Management (Hypercholesterolemia)\u003c\/td\u003e\n\u003ctd\u003eHuman Dietary Supplements \u0026amp; Nutraceuticals\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNotice of Allowance (Immune Support)\u003c\/td\u003e\n\u003ctd\u003eApril 26, 2021\u003c\/td\u003e\n\u003ctd\u003eImmune Response in Dairy Cattle\u003c\/td\u003e\n\u003ctd\u003eAnimal Feed Supplements Market (Projected \u003cstrong\u003e$58.96 billion\u003c\/strong\u003e by 2032)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eApplication No. 17\/465,457\u003c\/td\u003e\n\u003ctd\u003eUnder Prosecution\u003c\/td\u003e\n\u003ctd\u003eImproving Gut Health\u003c\/td\u003e\n\u003ctd\u003ePoultry Gut Health \/ Antibiotic-Free Feed Segment (Valued at \u003cstrong\u003e$4.5 billion\u003c\/strong\u003e in 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProprietary Algal Culture\/Extracts\u003c\/td\u003e\n\u003ctd\u003eOngoing Development\u003c\/td\u003e\n\u003ctd\u003eCanine Joint Health, Bovine Mastitis\u003c\/td\u003e\n\u003ctd\u003eCompanion Animal Vaccines Market (Valued at \u003cstrong\u003e$5.43 billion\u003c\/strong\u003e in 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eFinancial Context Related to IP Commercialization:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTrailing 12-Month Revenue (as of 30-Sep-2025): \u003cstrong\u003e$209K\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFY 2024 Revenue: \u003cstrong\u003e$157,220\u003c\/strong\u003e, representing a \u003cstrong\u003e468.61%\u003c\/strong\u003e increase from the prior year's \u003cstrong\u003e$27,650\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFY 2024 Losses: \u003cstrong\u003e-$13.38 million\u003c\/strong\u003e, an increase of \u003cstrong\u003e72.1%\u003c\/strong\u003e compared to 2023.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eZIVO Bioscience, Inc. (ZIVO) - VRIO Analysis: 6. Regulatory Compliance Asset (GRAS Status)\n\u003c\/h2\u003e\n\u003cp\u003eThe GRAS status pertains to ZIVO's proprietary algal biomass, previously branded as \u003cstrong\u003eKalgae™\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO Component\u003c\/th\u003e\n\u003cth\u003eAssessment\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAllows for near-term commercialization in the human food ingredient space without requiring lengthy clinical trials for safety clearance. Sales began in \u003cstrong\u003eJune 2023\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNo, many ingredients have GRAS, but ZIVO's is specific to their novel strain of algal biomass.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eModerately difficult; replicating the specific testing and dossier update (completed \u003cstrong\u003eMay 2023\u003c\/strong\u003e) takes time and money.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eYes, they are actively reviewing the status to support increases in the \u003cstrong\u003eallowable daily intake (ADI)\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eTemporary, as competitors can pursue their own GRAS or other clearances.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eSupporting Statistical and Financial Data:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe self-affirmed GRAS process for the algal biomass was initially completed in \u003cstrong\u003eNovember 2018\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe GRAS dossier was updated to current FDA standards in \u003cstrong\u003eMay 2023\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe updated GRAS designation was announced on \u003cstrong\u003eMay 30, 2023\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe Company reported revenue of \u003cstrong\u003e$27,650\u003c\/strong\u003e for the year 2023.\u003c\/li\u003e\n\u003cli\u003eResearch and development expenses for the year ended \u003cstrong\u003eDecember 31, 2024\u003c\/strong\u003e were \u003cstrong\u003e$3.1 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eGeneral and administrative expenses for the year ended \u003cstrong\u003eDecember 31, 2024\u003c\/strong\u003e were \u003cstrong\u003e$10.3 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe Company had \u003cstrong\u003eseven full-time employees\u003c\/strong\u003e as of the end of \u003cstrong\u003e2024\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe accumulated deficit was approximately \u003cstrong\u003e$137 million\u003c\/strong\u003e as of the end of \u003cstrong\u003e2024\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eZIVO Bioscience, Inc. (ZIVO) - VRIO Analysis: 7. Antibiotic-Free Market Positioning\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Aligns perfectly with global regulatory pressure against antibiotic overuse in livestock and strong consumer demand for natural alternatives.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMarket Segment\u003c\/th\u003e\n\u003cth\u003eValuation\/Size\u003c\/th\u003e\n\u003cth\u003eForecast\/CAGR\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAntibiotic-Free Livestock Feed\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$4.5 billion\u003c\/strong\u003e (2024)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$8.9 billion\u003c\/strong\u003e by 2033 (\u003cstrong\u003e8.2% CAGR\u003c\/strong\u003e)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCoccidiosis Annual Cost (Global)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$10 billion\u003c\/strong\u003e to \u003cstrong\u003e$17 billion\u003c\/strong\u003e (2020 estimate)\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Gut Health Alternatives Market (2021 Estimate)\u003c\/td\u003e\n\u003ctd\u003eApprox. \u003cstrong\u003e$8 billion\u003c\/strong\u003e annually\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal Poultry Vaccines Market\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$2.3 billion\u003c\/strong\u003e (2023)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$4.2 billion\u003c\/strong\u003e by 2032 (\u003cstrong\u003e7.1% CAGR\u003c\/strong\u003e)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e No, but ZIVO claims superior performance at cost parity, which is rare, especially given no commercially significant new technology for coccidiosis treatment has been introduced in the past \u003cstrong\u003e60 years\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Easy to imitate the claim, but hard to imitate the performance data, such as positive efficacy results from the \u003cstrong\u003e42-Day Validation Study\u003c\/strong\u003e with the non-antibiotic product candidate for coccidiosis in broiler chickens.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Yes, management highlights this convergence as an exceptional market opportunity, targeting a segment of the animal health market that could represent a massive potential global market for antibiotic antimicrobial alternatives.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary, dependent on maintaining a cost\/performance edge over other natural alternatives, with CEO confidence expressed in achieving results at \u003cstrong\u003ecost parity\u003c\/strong\u003e with conventional interventions.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eZIVO Bioscience reported revenue of \u003cstrong\u003e$157,220\u003c\/strong\u003e in 2024, representing an increase of \u003cstrong\u003e468.61%\u003c\/strong\u003e compared to the prior year's \u003cstrong\u003e$27,650\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eLosses for ZIVO Bioscience in 2024 were \u003cstrong\u003e-$13.38 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eAs of December 05, 2025, ZIVO Bioscience's Market Cap was \u003cstrong\u003e$38.89m\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eZIVO Bioscience, Inc. (ZIVO) - VRIO Analysis: 8. Full Value Chain Control Focus\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e: Committing to 'owning' the entire process from strain discovery through post-processing creates quality control and traceability, crucial for premium ingredients.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e: \u003cstrong\u003eYes\u003c\/strong\u003e, few R\u0026amp;D-focused firms maintain this level of process control commitment.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e: \u003cstrong\u003eDifficult\u003c\/strong\u003e, as it requires deep operational expertise across biology, cultivation, and extraction.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e: \u003cstrong\u003eYes\u003c\/strong\u003e, this philosophy guides their cultivation and development programs.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e: \u003cstrong\u003eSustained\u003c\/strong\u003e, as it builds organizational knowledge that is hard to replicate quickly.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (Latest Reported)\u003c\/th\u003e\n\u003cth\u003eUnit\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEmployee Count\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e7\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePersonnel\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTTM Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$209,025\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUSD (as of September 30, 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss (TTM)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-$8,486,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUSD (in thousands)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash \u0026amp; Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$57,222\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUSD (as of September 30, 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Current Liabilities\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3,614,268\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUSD (as of September 30, 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe commitment to full value chain control is evidenced by the scope of their R\u0026amp;D and proposed infrastructure:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe development program begins with strain discovery through validation, compliance, cultivation, to post-processing and productizing.\u003c\/li\u003e\n\u003cli\u003eThe cultivation model favors basic, cost-efficient models over complex fermentation systems.\u003c\/li\u003e\n\u003cli\u003eThe company has proposed the design, construction, and operation of large-scale, \u003cstrong\u003e140-hectare\u003c\/strong\u003e microalgae farms globally.\u003c\/li\u003e\n\u003cli\u003eZIVO commits to purchasing each farm's entire output for \u003cstrong\u003efive (5)\u003c\/strong\u003e years as it builds a global supply chain.\u003c\/li\u003e\n\u003cli\u003eThe ZIVO strain is stated to absorb roughly \u003cstrong\u003eone pound\u003c\/strong\u003e of carbon dioxide to produce roughly \u003cstrong\u003eone pound\u003c\/strong\u003e of quality protein.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eZIVO Bioscience, Inc. (ZIVO) - VRIO Analysis: 9. Management's High Financial Conviction\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Signals internal belief in the science and future value, which can be crucial for attracting external capital, especially given the $\\mathbf{\\$45.4M}$ market cap as of Nov 7, 2025.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e No, insider buying happens, but the public commitment is a specific action.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Easy to imitate; other management teams can buy stock.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Yes, the CEO and board have personally invested to demonstrate conviction.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e None, this is more of a positive signal than a true resource.\u003c\/p\u003e\n\n\u003cp\u003eThe conviction is evidenced by recent transactions, as detailed below:\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eInsider\u003c\/th\u003e\n\u003cth\u003eDate of Purchase\u003c\/th\u003e\n\u003cth\u003eShares Purchased\u003c\/th\u003e\n\u003cth\u003ePrice Per Share\u003c\/th\u003e\n\u003cth\u003eTotal Value\u003c\/th\u003e\n\u003cth\u003ePost-Transaction Indirect Holdings\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirector Laith L. Yaldoo (via HEP Investments LLC)\u003c\/td\u003e\n\u003ctd\u003e11\/28\/2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2,777\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$9.00\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$24,993\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e577,872\u003c\/strong\u003e shares\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirector Christopher Maggiore\u003c\/td\u003e\n\u003ctd\u003e10\/08\/2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e23,682\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eData Not Specified\u003c\/td\u003e\n\u003ctd\u003eData Not Specified\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e517,526\u003c\/strong\u003e shares\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe overall insider transaction history indicates \u003cstrong\u003e7 insider buys\u003c\/strong\u003e and \u003cstrong\u003e1 insider sell\u003c\/strong\u003e over the same period.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFinance:\u003c\/strong\u003e The financial context supporting the need for external capital, given management's conviction, includes key metrics as of September 30, 2025:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNet cash used in operations (first 9 months 2025): \u003cstrong\u003e$(2,173,204)\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eCash balance as of September 30, 2025: \u003cstrong\u003e$57,222\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eCash balance as of December 31, 2024: \u003cstrong\u003e$1,542,442\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eTotal Liabilities as of September 30, 2025: \u003cstrong\u003e$3,846,055\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eNet loss for the first 9 months of 2025: \u003cstrong\u003e$(6,884,474)\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eManagement estimate of funding needed over next 12 months: \u003cstrong\u003e$6.0 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516286787733,"sku":"zivo-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/zivo-vrio-analysis.png?v=1740233701","url":"https:\/\/dcf-model.com\/pt\/products\/zivo-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}